DWA
FUSN

Dorsey Wright & Associates’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Dorsey Wright & Associates’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-878
Closed -$2.28K – 302
2023
Q3 		$2.28K Sell
878
-4,011
-82% -$12.9K ﹤0.01% 283
2023
Q2 		$22.9K Buy
+4,889
New +$21.1K 0.01% 235

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Dorsey Wright & Associates's FUSN Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q4 2023, closing a stake of 878 shares — an estimated $2.28K sold.

Dorsey Wright & Associates first reported a position in FUSN in Q2 2023 and held it in 2 quarters. The position peaked at $22.9K in Q2 2023. 77 funds tracked by Wall St. Rank hold FUSN as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 878 Fusion Pharmaceuticals Inc. Common Shares shares in Q4 2023, an estimated $2.28K.
  • Dorsey Wright & Associates first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2023 and held it in 2 quarters.
  • Dorsey Wright & Associates's Fusion Pharmaceuticals Inc. Common Shares position peaked at $22.9K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.